Peripheral blood indices to predict PFS/OS with anlotinib as a subsequent treatment in advanced small-cell lung cancer.

Abstract

OBJECTIVE:

In the phase II ALTER-1202 (NCT03059797) trial, anlotinib significantly improved progression-free survival (PFS) and overall survival (OS) in patients with advanced small-cell lung cancer (SCLC) who underwent at least 2 previous chemotherapy cycles, when compared with a placebo group. To identify potential factors for predicting efficacy and prognosis with anlotinib treatment, we analyzed hematological indices at baseline and adverse events (AEs) over the course of anlotinib treatment.

METHODS:

Data were collected from March 2017 to April 2019 from a randomized, double-blind, placebo-controlled, multicenter, phase II trial of anlotinib. Eligible patients were randomly assigned 2:1 to receive anlotinib or placebo until disease progression, intolerable toxicity, or withdrawal of consent. The patients received anlotinib (12 mg) or an analogue capsule (placebo) orally once daily for 14 days every 3 weeks. The hematological indices at baseline and AEs that occurred in the initial 2 treatment cycles were recorded. The Kaplan-Meier test and Cox regression model were used to assess survival differences.

RESULTS:

A total of 82 patients (81 patients with complete data) were randomly assigned to receive anlotinib, with 38 receiving a placebo as a control. Multivariate analysis indicated that an elevated neutrophil to lymphocyte ratio > 7.75 and lactate dehydrogenase > 254.65 U/L at baseline were independent risk factors for PFS; basal elevated aspartate aminotransferase > 26.75 U/L, neuron specific enolase > 18.64 ng/mL, and fibrinogen > 4.645 g/L were independent risk factors for OS. During treatment, elevated γ glutamyltransferase and hypophosphatemia were independent predictors for a poor PFS, and elevated γ-glutamyl transferase and hypercholesterolemia were independent factors for OS.

CONCLUSIONS:

Our study preliminarily defined potential factors that affected the PFS and OS at baseline and during anlotinib treatment in patients with advanced SCLC. Our findings provide a basis for screening the dominant population and for dynamic efficacy monitoring with anlotinib therapy.

• Authors: Cuicui Zhang, Jing Wang, Xinyue Wang, Zhaoting Meng, Ying Cheng, Kai Li
• Journal: Cancer biology & medicine (Cancer Biol Med) Vol. 19 Issue 8 (07 24 2021) ISSN: 2095-3941 [Print] China
• PMID: 34302324 (Publication Type: Clinical Trial, Phase II, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
• Copyright: Copyright © 2022 Cancer Biology & Medicine.

Chemical References

• Indoles
• Quinolines
• anlotinib
• Fibrinogen
• Lactate Dehydrogenases
• gamma-Glutamyltransferase
• Aspartate Aminotransferases
• Phosphopyruvate Hydratase

Topics

• Aspartate Aminotransferases (therapeutic use)
• Carcinoma, Non-Small-Cell Lung (drug therapy)
• Fibrinogen (therapeutic use)
• Humans
• Indoles
• Lactate Dehydrogenases
• Lung Neoplasms (drug therapy)
• Phosphopyruvate Hydratase
• Progression-Free Survival
• Quinolines
• Small Cell Lung Carcinoma (drug therapy)
• Treatment Outcome
• gamma-Glutamyltransferase (therapeutic use)